Healthcare: The Super Bowl of Healthcare *** INDUSTRY FOCUS ***

TL;DR

Recap of the JP Morgan Healthcare Conference discussing AbbVie's reliance on HUMIRA and Johnson & Johnson's investment strategy.

Transcript

Kristine Harjes: The Super Bowl of healthcare; this is Industry Focus. Hello, everyone! Welcome to Industry Focus, healthcare edition. I'm your host, Kristine Harjes. I am joined by Motley Fool healthcare contributor Todd Campbell on the line via Skype. Todd, welcome back! Todd Campbell: Always happy to be here! Looking forward to today's conversat... Read More

Key Insights

• 😀 AbbVie faces challenges due to the patent expiration of HUMIRA, its top-selling drug.
• 👨‍🔬 Johnson & Johnson focuses on small acquisitions and collaborations for research and development.
• 🛄 Moonshot 2020 aims to revolutionize cancer treatment through innovative drug combinations.
• 📽️ Companies like Amgen and Celgene are involved in the Moonshot 2020 project.
• 💋 Independence Blue Cross and Bank of America's involvement in Moonshot marks a new collaboration between insurers and pharmaceutical companies.
• 👾 Combining drugs for cancer treatment is a potential game-changer in the industry.
• 😨 The emphasis on personalized care and targeted therapies is a growing trend in healthcare.

Questions & Answers

Q: What is the significance of the JP Morgan Healthcare Conference in the industry?

The conference allows companies to update investors on their healthcare initiatives, setting the tone for the year.

Q: How does AbbVie's reliance on HUMIRA pose a challenge for the company?

AbbVie faces challenges due to the impending patent expiration of HUMIRA, its top-selling drug.

Q: What investment strategy is Johnson & Johnson pursuing in the healthcare sector?

Johnson & Johnson is focusing on small acquisitions and collaborations for research and development, aiming to bring new drugs to market.

Q: What is the Moonshot 2020 project, and why is it significant?

Moonshot 2020 is a collaboration aiming to revolutionize cancer treatment by testing drug combinations and mapping genetic mutations for personalized care.

Summary & Key Takeaways

• The JP Morgan Healthcare Conference is a significant event in the industry, where companies update investors on their healthcare initiatives.

• AbbVie's reliance on HUMIRA, a top-selling drug, faces patent expiration challenges.

• Johnson & Johnson's focus on small acquisitions and collaborations for research and development is highlighted.